{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,10,30]],"date-time":"2025-10-30T16:26:33Z","timestamp":1761841593342},"reference-count":12,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2019,3,1]],"date-time":"2019-03-01T00:00:00Z","timestamp":1551398400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":["clinicalkey.jp","jocn-journal.com","clinicalkey.com","clinicalkey.es","clinicalkey.com.au","clinicalkey.fr","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Journal of Clinical Neuroscience"],"published-print":{"date-parts":[[2019,3]]},"DOI":"10.1016\/j.jocn.2018.10.128","type":"journal-article","created":{"date-parts":[[2018,11,3]],"date-time":"2018-11-03T02:54:20Z","timestamp":1541213660000},"page":"112-113","update-policy":"http:\/\/dx.doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":4,"special_numbering":"C","title":["Seroconversion of JCV antibodies is strongly associated to natalizumab therapy"],"prefix":"10.1016","volume":"61","author":[{"given":"Yara Dadalti","family":"Fragoso","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Joseph B. Bidin","family":"Brooks","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Audred C. Biondo","family":"Eboni","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Leticia","family":"Fezer","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Paulo Diniz","family":"da Gama","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sidney","family":"Gomes","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Marcus Vinicius M.","family":"Gon\u00e7alves","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Suzana Nunes","family":"Machado","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Rogerio Rizo","family":"Morales","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Maria Lucia Vellutini","family":"Pimentel","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Heloisa Helena","family":"Ruocco","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Gutemberg Augusto","family":"Santos","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Simone","family":"Scherpenhuijzen","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Nise Alessandra Carvalho","family":"Sousa","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"issue":"12","key":"10.1016\/j.jocn.2018.10.128_b0005","doi-asserted-by":"crossref","first-page":"2409","DOI":"10.1007\/s00415-017-8643-4","article-title":"Natalizumab therapy is associated with changes in serum JC virus antibody indices over time","volume":"264","author":"Peters","year":"2017","journal-title":"J Neurol"},{"key":"10.1016\/j.jocn.2018.10.128_b0010","doi-asserted-by":"crossref","first-page":"257","DOI":"10.1016\/j.jocn.2017.08.006","article-title":"Anti-JCV antibody serostatus and longitudinal evaluation in a Portuguese Multiple Sclerosis population","volume":"45","author":"Correia","year":"2017","journal-title":"J Clin Neurosci"},{"issue":"9","key":"10.1016\/j.jocn.2018.10.128_b0015","doi-asserted-by":"crossref","first-page":"1196","DOI":"10.1111\/ene.13355","article-title":"John Cunningham virus conversion in relation to natalizumab concentration in multiple sclerosis patients","volume":"24","author":"van Kempen","year":"2017","journal-title":"Eur J Neurol"},{"issue":"6","key":"10.1016\/j.jocn.2018.10.128_b0020","doi-asserted-by":"crossref","first-page":"1079","DOI":"10.1111\/ene.12988","article-title":"High cumulative JC virus seroconversion rate during long-term use of natalizumab","volume":"23","author":"Vennegoor","year":"2016","journal-title":"Eur J Neurol"},{"issue":"1","key":"10.1016\/j.jocn.2018.10.128_b0025","doi-asserted-by":"crossref","DOI":"10.1212\/NXI.0000000000000195","article-title":"Therapy with natalizumab is associated with high JCV seroconversion and rising JCV index values","volume":"3","author":"Schwab","year":"2016","journal-title":"Neurol Neuroimmunol Neuroinflamm"},{"issue":"7","key":"10.1016\/j.jocn.2018.10.128_b0030","doi-asserted-by":"crossref","first-page":"822","DOI":"10.1177\/1352458513505353","article-title":"JC-virus seroconversion in multiple sclerosis patients receiving natalizumab","volume":"20","author":"Outteryck","year":"2014","journal-title":"Mult Scler"},{"issue":"14","key":"10.1016\/j.jocn.2018.10.128_b0035","doi-asserted-by":"crossref","first-page":"1833","DOI":"10.1177\/1352458515599681","article-title":"Anti-JC virus antibody titres increase over time with natalizumab treatment","volume":"21","author":"Raffel","year":"2015","journal-title":"Mult Scler"},{"issue":"11","key":"10.1016\/j.jocn.2018.10.128_b0040","doi-asserted-by":"crossref","first-page":"1199","DOI":"10.1136\/jnnp-2012-304332","article-title":"Changes to anti-JCV antibody levels in a Swedish national MS cohort","volume":"84","author":"Warnke","year":"2013","journal-title":"J Neurol Neurosurg Psychiatry"},{"issue":"5","key":"10.1016\/j.jocn.2018.10.128_b0045","doi-asserted-by":"crossref","first-page":"563","DOI":"10.1177\/1352458517728814","volume":"24","author":"Schwab","year":"2018","journal-title":"Mult Scler"},{"issue":"5","key":"10.1016\/j.jocn.2018.10.128_b0050","doi-asserted-by":"crossref","first-page":"391","DOI":"10.1111\/ane.12475","article-title":"Anti-JC virus seroprevalence in a Finnish MS cohort","volume":"133","author":"Kolasa","year":"2016","journal-title":"Acta Neurol Scand"},{"issue":"6","key":"10.1016\/j.jocn.2018.10.128_b0055","doi-asserted-by":"crossref","first-page":"645","DOI":"10.1007\/s13365-014-0268-0","article-title":"JC virus urinary excretion and seroprevalence in natalizumab-treated multiple sclerosis patients","volume":"21","author":"Delbue","year":"2015","journal-title":"J Neurovirol"},{"issue":"2","key":"10.1016\/j.jocn.2018.10.128_b0060","doi-asserted-by":"crossref","first-page":"158","DOI":"10.1111\/eci.12721","article-title":"Study of the anti-JCV antibody levels in a Spanish multiple sclerosis cohort","volume":"47","author":"Dominguez-Mozo","year":"2017","journal-title":"Eur J Clin Invest"}],"container-title":["Journal of Clinical Neuroscience"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0967586818310828?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0967586818310828?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2019,2,15]],"date-time":"2019-02-15T13:21:35Z","timestamp":1550236895000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0967586818310828"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,3]]},"references-count":12,"alternative-id":["S0967586818310828"],"URL":"https:\/\/doi.org\/10.1016\/j.jocn.2018.10.128","relation":{},"ISSN":["0967-5868"],"issn-type":[{"value":"0967-5868","type":"print"}],"subject":[],"published":{"date-parts":[[2019,3]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Seroconversion of JCV antibodies is strongly associated to natalizumab therapy","name":"articletitle","label":"Article Title"},{"value":"Journal of Clinical Neuroscience","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jocn.2018.10.128","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2018 Elsevier Ltd. All rights reserved.","name":"copyright","label":"Copyright"}]}}